Novo Nordisk stock news
On May 14, 2026, Novo Nordisk (NVO) improved its full--year 2026 financial outlook, now projecting a narrower decline in adjusted sales and operating profit of 4% to 12%, compared to the previous forecast of 5% to 13%. This upward revision is primarily attributed to the robust commercial performance of the Wegovy pill, which has secured over 2 million prescriptions since its January launch. Additionally, the company announced a 37% increase in its semiannual dividend to $1.04 per American Depositary Receipt (ADR), reflecting management's confidence in sustained volume growth despite U.S. pricing headwinds from the "Most Favored Nation" agreement.